Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.

ABSTRACT:

Background

Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progression on HER2-directed therapy for advanced HER2-positive breast cancer. Data from several phase II and III trials evaluating HER2-directed therapy following second-line T-DM1 have recently become available.

Methods

We performed a systematic search of the published and presented literature to identify phase II and phase III trials assessing novel HER2-targeted agents as third-line therapy or beyond for HER2-positive advanced breast cancer using search terms 'breast cancer' AND 'HER2' AND 'advanced' AND ('phase II' OR 'phase III').

Results

Eight clinical trials reporting efficacy outcomes on third-line or greater HER2-directed therapy for HER2-positiv

SUBMITTER: Simmons C 

PROVIDER: S-EPMC8753087 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature